Bispecific SIGLEC7xFSHR NK cell engager for ovarian cancer

A bispecific antibody that simultaneously engages and blocks SIGLEC7, an inhibitory receptor expressed on human NK cells, and binds FSHR, and ovarian hormone receptor, could help treat ovarian cancer by increasing NK-mediated anti-tumor cytotoxicity.

Screening of fully humanized, codon- and RNA-optimized anti-SIGLEC7 antibodies identified a mAb that increased NK cell-mediated killing of an ovarian cancer cell line with an EC50 of 82.67 nM, and this mAb’s single-chain variable fragment (scFV) was incorporated into a bispecific construct with the scFV of a previously discovered anti-FSHR mAb to simultaneously target SIGLEC7 and FSHR. ...